Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAD/MAD study of REC-3964 in healthy volunteers
NL-OMON53684Phase 1Completed
- Sponsor
- Recursion Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Clostridioides difficile colitis (CDI) comparing REC-3964 with Placebo (2 arms). Primary endpoint: Safety and tolerability of single ascending doses and multiple ascending doses of REC-3964. Started Aug 2022; status: completed.
02
Drugs
REC-163964
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on NL-OMON53684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53684.